Singapore Technologies Engineering Ltd. ADS (SGGKY)
Singapore Technologies Engineering Ltd. ADS (SGGKY) Financials Nov 11, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Singapore Technologies Engineering Ltd. ADS
Fiscal year is January-December. All values SGD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 5.55B 5.98B 5.99B 6.38B 6.63B
Cost of Goods Sold (COGS) incl. D&A 4.39B 4.72B 4.68B 4.92B 5.21B
COGS excluding D&A 4.22B 4.59B 4.54B 4.79B 5.07B
Depreciation & Amortization Expense 162.76M 132.03M 135.06M 137.1M 142.04M
Depreciation 150.99M 120.94M 125.78M 123.95M 127.18M
Amortization of Intangibles 11.42M 11.09M 9.28M 13.15M 14.87M
Gross Income 1.16B 1.26B 1.31B 1.46B 1.42B
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 579.19M 572.89M 591.33M 674.71M 642.24M
Research & Development 82.24M 98.17M 96.25M 95.72M 101.43M
Other SG&A 496.95M 474.72M 495.09M 578.99M 540.81M
Other Operating Expense 84.61M 64.7M 61.05M 68.76M 100.78M
Unusual Expense 11.55M 43.79M 58.94M 57.1M 10.04M
EBIT after Unusual Expense (11.55M) (43.79M) (58.94M) (57.1M) (10.04M)
Non Operating Income/Expense 64.95M 45.73M 51.31M 49.28M 60.7M
Non-Operating Interest Income 12.69M 20.46M 20.19M 26.15M 23.32M
Equity in Affiliates (Pretax) - 44.12M 34.62M 40.61M -
Interest Expense 56.12M 64.91M 50.62M 49.5M 44.24M
Gross Interest Expense 56.12M 64.91M 50.62M 49.5M 44.24M
Interest Capitalized 0 0 0 0 0
Pretax Income 507.68M 627.48M 655.23M 723.06M 698.61M
Income Tax 90.47M 122.62M 114.56M 138.44M 138.15M
Income Tax - Current Domestic 90.38M 133.67M 107.96M 150.49M 139.91M
Income Tax - Current Foreign - - - - -
Income Tax - Deferred Domestic 91,000 (11.05M) 6.6M (12.05M) (1.77M)
Income Tax - Deferred Foreign - - - - -
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 39.19M - - - 31.08M
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 456.4M 504.85M 540.66M 584.62M 591.55M
Minority Interest Expense 12.47M 13.85M 13.12M 8.44M 10.71M
Net Income 443.93M 491.01M 527.54M 576.18M 580.83M
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 443.93M 491.01M 527.54M 576.18M 580.83M
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 443.93M 491.01M 527.54M 576.18M 580.83M
EPS (Basic) 0.15 0.16 0.17 0.19 0.19
Basic Shares Outstanding 3B 3.03B 3.05B 3.07B 3.1B
EPS (Diluted) 0.15 0.16 0.17 0.19 0.19
Diluted Shares Outstanding 3.01B 3.04B 3.06B 3.08B 3.11B
EBITDA 660.47M 757.89M 793.73M 850.73M 822.42M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...
Continue Reading
Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....
Continue Reading
A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...
Continue Reading
Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...
Continue Reading
Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...
Continue Reading
Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...
Continue Reading
Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....
Continue Reading
Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...
Continue Reading
The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...
Continue Reading
In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...
Continue Reading
Top 5 Most Recently Viewed Articles
Understanding Inflation Trends and Risks Monitoring inflation trends has become increasingly important in the current economic climate, where the Consumer Price Index (CPI) had previously surged to 9.0%. Now, with inflation levels around 2.7%, many are left observing potential shifts in macroeconomic conditions. As government policies shift, especially with new leadership...
Continue Reading
Cornish Metals Strengthens Its Financial Position Vancouver-based Cornish Metals Inc. (TSX-V: CUSN, LSE: CUSN) is excited to announce a significant move to bolster its financial stature. The company, known for its focus on mineral exploration and development, specifically its permitted South Crofty tin project, has exercised stock options resulting in the issuance of...
Continue Reading
Jackson Physician Search Celebrated as a Premier Workplace Jackson Physician Search has achieved an impressive milestone by earning No. 2 ranking among medium-sized companies and eighth overall in the esteemed healthcare sector, in the annual Modern Healthcare awards for best places to work. This announcement follows the company's remarkable ten consecutive years on this...
Continue Reading
Revolutionizing AI Applications with CAMARA and MCP CAMARA, an open-source community project, is leading the charge in bridging artificial intelligence (AI) with telecommunication networks via modern APIs. Their innovative approach is outlined in a newly released white paper asserting the capabilities of their Model Context Protocol (MCP) combined with network APIs. The...
Continue Reading
Cohen & Steers Infrastructure Fund Overview Cohen & Steers Infrastructure Fund, Inc. (NASDAQ: UTF) provides valuable investment options focusing on infrastructure. As an influential player in capital assets, the Fund aims to meet the needs of investors looking for sustainable income and growth. Understanding the sources of distribution is essential for shareholders...
Continue Reading